Wedmont Private Capital Purchases New Shares in Roivant Sciences Ltd. (NASDAQ:ROIV)

Wedmont Private Capital acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 11,295 shares of the company’s stock, valued at approximately $134,000.

Other institutional investors have also recently bought and sold shares of the company. Mutual of America Capital Management LLC raised its position in shares of Roivant Sciences by 0.4% in the second quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after buying an additional 1,142 shares in the last quarter. GAMMA Investing LLC raised its holdings in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Roivant Sciences by 23.2% during the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after acquiring an additional 1,603 shares during the period. Covestor Ltd grew its holdings in shares of Roivant Sciences by 9.1% during the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company’s stock worth $222,000 after purchasing an additional 1,605 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares during the period. Institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and an average price target of $17.93.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 177,704 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16. Following the sale, the chief operating officer now owns 740,976 shares of the company’s stock, valued at approximately $8,550,863.04. The trade was a 19.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the stock in a transaction dated Monday, January 13th. The shares were bought at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the acquisition, the director now directly owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 1,942,629 shares of company stock valued at $23,071,486. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Stock Up 2.4 %

Shares of ROIV stock opened at $11.15 on Friday. The business has a fifty day simple moving average of $11.79 and a 200 day simple moving average of $11.58. The company has a market cap of $8.12 billion, a P/E ratio of 1.97 and a beta of 1.27. Roivant Sciences Ltd. has a twelve month low of $9.69 and a twelve month high of $13.06.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.